Quality indicators for early stage Hodgkin's lymphoma

Roos, Daniel; Tee, Hui

doi:10.1111/1754-9485.12602

Cited by 3 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This review included various study designs: population‐based cohort studies that typically used registry data ( n = 12 57–59,62–65,67–69,71,118 ), multicenter cohort studies ( n = 4 54,56,61,66 ), and case‐series which followed patients from a single institution ( n = 4 55,60,70,72 ) (Table 1). The studies were conducted in New South Wales (NSW) and the Australian Capital Territory (ACT) ( n = 10 54–56,59,61,65–67,71,118 ), South Australia (SA) ( n = 4 62,63,70,72 ), Victoria (VIC) ( n = 3 57,60,69 ), Australia‐wide ( n = 2 64,68 ), and Queensland (QLD) ( n = 1 58 ). The Australia Cancer Network (ACN) CPGs (which were developed in partnership with the National Health and Medical Research Council (NHMRC)) ( n = 7), National Comprehensive Cancer Network (NCCN) CPGs ( n = 7), and NHMRC CPGs ( n = 5) were the most commonly used CPGs across the 20 included studies (with 7 studies referring to more than 1 CPG) (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Of the 20 included studies, 16 assessed factors associated with receipt of GRT, 54,56–65,67–69,71,118 whereas 4 studies did not 55,66,70,72 (Table 4). Factors associated with receipt of GRT have been categorized according to the WHO's five dimensions of adherence framework: patient factors, health condition factors, healthcare system and team factors, socioeconomic factors, and medical therapy factors 73 (Table 4 and Figure 3).…”

Section: Resultsmentioning

confidence: 99%

“…Of the 20 included studies, 16 assessed factors associated with receipt of GRT, 54,[56][57][58][59][60][61][62][63][64][65][67][68][69]71,118 whereas 4 studies did not 55,66,70,72 (Table 4).…”

Section: Factors Significantly Associated With Receipt Of Grtmentioning

confidence: 99%

“…Of the 20 studies included in the final analysis, the majority of studies assessed adherence to lung cancer treatment CPGs (n = 6 [54][55][56][57][58]118 ), cervical cancer (n = 4 [58][59][60][61] ), colorectal cancer (CRC) (n = 4 [62][63][64][65] ), and breast cancer (n = 3 [66][67][68] ). Two studies assessed adherence to lymphoma CPGs, 69,70 another assessed melanoma CPGs, 71 and another one assessed prostate cancer CPGs. 72 One study assessed adherence to both cervical and lung cancer 58 (Table 1).…”

Section: Characteristics Of Included Studies Quality Assessment and R...mentioning

confidence: 99%

See 3 more Smart Citations

Rates of adherence to cancer treatment guidelines in Australia and the factors associated with adherence: A systematic review

Bierbaum

Rapport

Arnolda

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Adherence to cancer treatment clinical practice guidelines (CPGs) varies enormously across Australia, despite being associated with improved patient outcomes. This systematic review aims to characterize adherence rates to active‐cancer treatment CPGs in Australia and related factors to inform future implementation strategies. Five databases were systematically searched, abstracts were screened for eligibility, a full‐text review and critical appraisal of eligible studies performed, and data extracted. A narrative synthesis of factors associated with adherence was conducted, and the median adherence rates within cancer streams calculated. A total of 21,031 abstracts were identified. After duplicates were removed, abstracts screened, and full texts reviewed, 20 studies focused on adherence to active‐cancer treatment CPGs were included. Overall adherence rates ranged from 29% to 100%. Receipt of guideline recommended treatments was higher for patients who were younger (diffuse large B‐cell lymphoma [DLBCL], colorectal, lung, and breast cancer); female (breast and lung cancer), and male (DLBCL and colorectal cancer); never smokers (DLBCL and lung cancer); non‐Indigenous Australians (cervical and lung cancer); with less advanced stage disease (colorectal, lung, and cervical cancer), without comorbidities (DLBCL, colorectal, and lung cancer); with good‐excellent Eastern Cooperative Oncology Group performance status (lung cancer); living in moderately accessible places (colon cancer); and; treated in metropolitan facilities (DLBLC, breast and colon cancer). This review characterized active‐cancer treatment CPG adherence rates and associated factors in Australia. Future targeted CPG implementation strategies should account for these factors, to redress unwarranted variation particularly in vulnerable populations, and improve patient outcomes (Prospero number: CRD42020222962).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Factors Significantly Associated With Receipt Of Grtmentioning

confidence: 99%

Section: Characteristics Of Included Studies Quality Assessment and R...mentioning

confidence: 99%

See 2 more Smart Citations

Rates of adherence to cancer treatment guidelines in Australia and the factors associated with adherence: A systematic review

Bierbaum

Rapport

Arnolda

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…A quality indicator is a measurable element of practice performance for which there is evidence or consensus that it can be used to assess the quality of care provided. 19 Quality indicators have been developed for non-HL 20 and proposed for early-stage HL with an emphasis on radiotherapy, 21 but there are no well-established quality indicators for medical management of HL. We based our assessment here on adherence to the nationally endorsed protocol adapted from evidence-based guidelines and benchmarks extrapolated from other available sources.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation

DeBoer

Shyirambere²,

Driscoll

et al. 2020

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Hodgkin lymphoma (HL) is highly curable in high-income countries (HICs), yet many patients around the world do not have access to therapy. In 2012, cancer care was established at a rural district hospital in Rwanda through international collaboration, and a treatment protocol using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) without radiotherapy was implemented. METHODS We conducted a retrospective cohort study of all patients with confirmed HL seen at Butaro Hospital from 2012 to 2018 to evaluate quality indicators and clinical outcomes. RESULTS Eighty-five patients were included (median age, 16.8 years; interquartile range, 11.0-30.5 years). Ten (12%) were HIV positive. Most had B symptoms (70%) and advanced stage (56%) on examination and limited imaging. Of 21 specimens evaluated for Epstein-Barr virus, 14 (67%) were positive. Median time from biopsy to treatment was 6.0 weeks. Of 73 patients who started ABVD, 54 (74%) completed 6 cycles; the leading reasons for discontinuation were treatment abandonment and death. Median dose intensity of ABVD was 92%. Of 77 evaluable patients, 33 (43%) are in clinical remission, 27 (36%) are deceased, and 17 (22%) were lost to follow-up; 3-year survival estimate is 63% (95% CI, 50% to 74%). Poorer performance status, advanced stage, B symptoms, anemia, dose intensity < 85%, and treatment discontinuation were associated with worse survival. CONCLUSION Treating HL with standard chemotherapy in a low-resource setting is feasible. Most patients who completed treatment experienced a clinically significant remission with this approach. Late presentation, treatment abandonment, and loss to follow-up contribute to the discrepancy in survival compared with HICs. A strikingly younger age distribution in our cohort compared with HICs suggests biologic differences and warrants further investigation.

show abstract

System Performance Indicators for Adolescent and Young Adult Cancer Care and Control: A Scoping Review

Rae

Shah

Pauw

et al. 2020

Journal of Adolescent and Young Adult Oncology

View full text Add to dashboard Cite

Quality indicators for early stage Hodgkin's lymphoma

Abstract: The chosen QIs for ESHL proved to be practicable to apply in this single centre review where overall compliance was high, and excellent in the latter half of the study period. We would encourage reporting of raw and corrected QI scores.

Cited by 3 publications

References 16 publications

Rates of adherence to cancer treatment guidelines in Australia and the factors associated with adherence: A systematic review

Rates of adherence to cancer treatment guidelines in Australia and the factors associated with adherence: A systematic review

Treatment of Hodgkin Lymphoma With ABVD Chemotherapy in Rural Rwanda: A Model for Cancer Care Delivery Implementation

System Performance Indicators for Adolescent and Young Adult Cancer Care and Control: A Scoping Review

Contact Info

Product

Resources

About